677 Phase II trial assessing safety, efficacy and immune correlates of heterologous prime-boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizumab for advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal cancer
Regular and Young Investigator Award Abstracts | October 31, 2023 | Volume: No volume available | Issue: No issue available | Pages: A768-A768
10.1136/jitc-2023-sitc2023.0677